Search

Your search keyword '"Michael D. Ezekowitz"' showing total 358 results

Search Constraints

Start Over You searched for: Author "Michael D. Ezekowitz" Remove constraint Author: "Michael D. Ezekowitz"
358 results on '"Michael D. Ezekowitz"'

Search Results

51. Urgent surgery or procedures in patients taking dabigatran or warfarin: Analysis of perioperative outcomes from the RE-LY trial

52. Periprocedural management of anticoagulation in patients taking novel oral anticoagulants: Review of the literature and recommendations for specific populations and procedures

53. Patients With Atrial Fibrillation

54. Edoxaban therapy increases treatment satisfaction and reduces utilization of healthcare resources: an analysis from the EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of atrial fibrillation (ENSURE-AF) study

55. Stroke prevention in atrial fibrillation

56. Atrial Fibrillation Burden: Moving Beyond Atrial Fibrillation as a Binary Entity: A Scientific Statement From the American Heart Association

57. Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory Drug Therapy in Patients With Atrial Fibrillation

58. Frequency and Outcomes of Reduced Dose Non–Vitamin K Antagonist Anticoagulants: Results From ORBIT‐AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II)

59. Comparison of bleeding risk scores in patients with atrial fibrillation: insights from the RE-LY trial

60. Dabigatran etexilate and reduction in serum apolipoprotein B

61. Comparison of Characteristics and Outcomes of Dabigatran Versus Warfarin in Hypertensive Patients With Atrial Fibrillation (from the RE-LY Trial)

62. Changes in Renal Function in Patients With Atrial Fibrillation

63. Edoxaban versus warfarin in patients with atrial fibrillation

64. Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure

65. Anemia predicts thromboembolic events, bleeding complications and mortality in patients with atrial fibrillation: insights from the RE‐LY trial

66. Efficacy and Safety of Dabigatran Etexilate vs. Warfarin in Asian RE-LY Patients According to Baseline Renal Function or CHADS2 Score

67. Association of of Atrial Fibrillation Clinical Phenotypes With Treatment Patterns and Outcomes: A Multicenter Registry Study

68. The impact of IMPACT-AF

69. P6369The relationship of renal function to outcome: a post hoc analysis from the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion Of Atrial Fibrillation (ENSURE-AF) study

70. 5770A novel biomarker-based risk score to predict death in patients with atrial fibrillation: Insights from the ARISTOTLE and RE-LY trials

71. P6365Clinical predictors of left atrium thrombi in patients scheduled for cardioversion of atrial fibrillation: a subanalysis from the ENSURE-AF study

72. Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time-A RE-LY trial analysis

73. Internal Carotid Artery and Sphenoidal Emissary (Vesalian) Vein Fistula Mimicking a Carotid-Cavernous Sinus Fistula

74. Abstract 057: Understanding of Treatment Strategies Among Patients Newly Diagnosed With Atrial Fibrillation: Findings From SATELITTE

75. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: Part 1

76. Short-term dabigatran interruption before cardiac rhythm device implantation: Multi-centre experience from the RE-LY trial

77. The relationship of renal function to outcome:A post hoc analysis from the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study

78. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation:part 2

79. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary

80. Novel Anticoagulants Eliminate the Need for Left Atrial Appendage Exclusion Devices

81. Reasons for warfarin discontinuation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)

82. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation

83. Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack

84. Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation

85. The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients

86. Impact of Atrial Fibrillation in Patients With ST-Elevation Myocardial Infarction Treated With Percutaneous Coronary Intervention (from the HORIZONS-AMI [Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction] Trial)

87. STROKE RISK PREDICTION IN PATIENTS WITH ATRIAL FIBRILLATION AND RHEUMATIC HEART DISEASE: RESULTS FROM THE RE-LY AF REGISTRY

88. Association Between Warfarin Control Metrics and Atrial Fibrillation Outcomes in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation

89. NON VITAMIN K ORAL ANTICOAGULANTS ARE NOT ASSOCIATED WITH INCREASED RISK OF PERIOPERATIVE BLEEDING IN PATIENTS UNDERGOING CARDIAC SURGERY

90. CHARACTERISTICS OF AF PATIENTS WITH LARGE IMPROVEMENT IN SYMPTOMS AT ONE YEAR: SUPER-RESPONSE IN THE ORBIT-AF REGISTRY

91. ASSOCIATION BETWEEN GUIDELINE-DIRECTED MEDICAL THERAPIES FOR COMORBID CONDITIONS AND CLINICAL OUTCOMES AMONG INDIVIDUALS WITH ATRIAL FIBRILLATION

92. Adding Rigor to Stroke Risk Prediction in Atrial Fibrillation

93. Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin

94. Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE‐LY trial

95. The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study

96. Dabigatran Versus Warfarin

97. Rate versus rhythm control for management of atrial fibrillation in clinical practice: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry

98. Effects of dabigatran according to age in atrial fibrillation

99. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial

100. Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation

Catalog

Books, media, physical & digital resources